share_log

Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair

Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair

Alvotech与Advanz Pharma就向Xolair提出的生物仿制药达成商业化协议
Benzinga Real-time News ·  2023/02/06 04:28

Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand

Advanz Pharma 将在欧洲经济区、英国、瑞士、加拿大、澳大利亚和新西兰将 Xolair(omalizumab)的拟议生物仿制药 AVT23 商业化

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发